

Date: 9th May, 2025

To,
Department of Corporate Services,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai-400 001

Scrip Code: 524604

Dear Sir/Madam,

Sub.: Outcome of Board of Directors Meeting of Adline Chem Lab Limited("the Company")

Dear Sir/ Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Friday, 9th May, 2025 at Registered Office of the Company has inter alia considered and approved the following businesses:

- (1) **Audited Financial Results along with Audit Report of the Company for the Quarter and Financial year ended 31st March, 2025.**

A copy of the Audited Financial Results of the Company for the Quarter and Financial year ended 31st March, 2025 along with statements of Assets and Liabilities and Auditor's Report are enclosed herewith as **Annexure – A**. These results are also being uploaded on the Company Website at www.adlinechem.com.

- (2) **Appointment of M/s. Rahul Doshi & Co, Chartered Accountants (FRN:150982W, Membership No: 117160) as Internal Auditor of the Company for the Financial Year 2025-26.**

The Board, based on the recommendation of Audit Committee in their meeting held today i.e., 9th May, 2025 has approved the appointment of M/s. Rahul Doshi & Co, Chartered Accountants(FRN: 150982W, Membership No: 117160) as Internal Auditor of the Company for the Financial Year 2025-26.

The details as required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular Number SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 are enclosed herewith as **Annexure - B**.

- (3) **Appointment of M/s Jitendra Parmar & Associates, Practicing Company Secretaries(FRN: S2023GJ903900, Membership No: F11336, COP No.: 15863) as Secretarial Auditor of the Company for the Financial Year 2024-25**

The Board, based on the recommendation of Audit Committee in their meeting held today i.e., 9th May, 2025 has approved the appointment of M/s. Jitendra Parmar & Associates, Practicing Company Secretaries (FRN - S2023GJ903900, Membership No:- F11336, COP – 15863,) as Secretarial Auditor of the Company for the Financial Year 2024-25 in place of M/s Jay Pandya and Associates, Company Secretary (Firm Registration No. S2024GJ963300).

CIN : L24231GJ1988PLC010956

ADLINE CHEM LAB LIMITED (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.
Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com

The details as required under Regulation 30 of the Listing Regulations, read with SEBI Master Circular Number SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 are enclosed herewith as **Annexure - C**.

(4) Resignation of Mrs. Ritu Singh as Company Secretary of the Company

The Board took note of the resignation tendered by Mrs. Ritu Singh who has resigned from the position of the Company Secretary of the Company with effect from 22nd April, 2025.

The meeting of Board of Directors of the Company commenced at 5:00 P.M. and concluded at 8:00 P.M.

You are requested to kindly take the same on record and acknowledge.

Yours faithfully,

Thanking You,

For, Adline Chem Lab Limited


Pathak Sarang Digitally signed by Pathak
Sarang Bharat
Date: 2025.05.09 20:02:35
+05'30'
Bharat

Sarang Bharatbhai Pathak
Managing Director
DIN: 02663344

Encl: as above

The Board of Directors**ADLINE CHEMLAB LIMITED****Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended March 31, 2025 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.




4. Based on our review conducted as above, nothing except for the point no. 5 & 6 stated below has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter:

5. We draw attention to the material modifications in the contract entered into by the Company with Vivanza Lifescience Private Limited, an unlisted entity within the group. The original transaction was conducted in the ordinary course of business for which the entities have entered into an agreement and complies with the provisions of Section 188 of the Companies Act, 2013. The Company has neither obtained prior shareholders' approval for this transaction nor subsequent material modifications as set forth in Regulation 23(4) of the Listing Regulation Act, 2015. Our opinion is not modified in respect of this matter.
6. The statement includes the financial results for the quarter ended 31st March 2025, being the balancing figures between the audited figures in respect of full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this.

**For Jain Kedia & Sharma
Chartered Accountants
FRN: 103920W**



Tarak

**Tarak Shah
Partner**

**Membership No. 182100
UDIN:25182100BMODAD2312**

**Place: Ahmedabad
Date: May 09, 2025**

" Annexure - A "

ADLINE CHEMLAB LIMITED Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054 CIN: L24231G1988PLC010956 Ph.No: 079-26870952/54 Email Id: secretarial.adlinechemlab@gmail.com Website: www.adlinechem.com STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March, 2025 (Rs in Lakhs)					
Particulars	Quarter Ended			Year Ended	
	31st March 2025	31st Dec 2024	31st March 2024	31st Mar 2025	31st March 2024
	Audited	Unaudited	Restated	Audited	Restated
Revenue from operations					
Other income	24.89			24.89	0.01
Total Income	24.89			24.89	0.01
Expenses					
Cost of materials consumed					
Purchase of Stock in Trade					
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress					
Employee benefits expense	4.68	4.72	4.27	17.64	4.56
Finance costs	2.94	1.48	3.23	13.15	12.44
Depreciation and amortization expense					
Other expenses	1.16	4.95	5.13	14.70	13.49
Total Expenses	8.72	13.14	9.62	45.46	30.29
Profit/(loss) before exceptional items and tax	16.17	(13.14)	(9.62)	(20.57)	(30.28)
Exceptional Items					
Profit/(loss) before tax	16.17	(13.14)	(9.62)	(20.57)	(30.28)
Tax expense:	(0.27)	(0.00)	(0.84)	(7.35)	(3.10)
Current tax					
Deferred tax	5.36	-0.88	(0.94)	2.78	(3.16)
Prior period tax	-10.13			-10.13	0.07
Profit (Loss) for the period from continuing operations	20.94	(12.26)	(8.77)	(13.22)	(27.18)
Profit/(loss) from discontinued operations					
Tax expense of discontinued operations					
Profit/(loss) from Discontinued operations (after tax)					
Profit/(loss) for the period	20.94	(12.26)	(8.77)	(13.22)	(27.18)
Other Comprehensive Income	(0.28)	0.46	0.05	1.10	0.05
Items that will not be reclassified to profit or loss (Net of tax)	(0.28)	0.46	0.05	1.46	0.05
Benefit due to actuarial valuation of gratuity	(0.37)	0.01	0.06	(0.37)	0.06
Share of tax	0.09	(0.15)	(0.02)		(0.02)
Items that will be reclassified in profit or loss (Net of tax)					
Total Comprehensive Income for the period	20.66	(11.80)	(8.73)	(12.12)	(27.13)
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00	585.00
Earnings per equity share (Not Annualised)					
Basic	0.04	(0.02)	(0.01)	(0.02)	(0.05)
Diluted	0.04	(0.02)	(0.01)	(0.02)	(0.05)


Notes:



- This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended March 31, 2025.
- These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on May 09, 2025, and approved by the Board of Directors at its meeting held on May 09, 2025. The Statutory Auditors Report does not have any qualification/modification.
- Other income comprises of:

Particulars	Quarter Ended			Year Ended	
	31st March 2025	31st Dec 2024	31st March 2024	31st Mar 2025	31st March 2024
Change due to Modification of Financial liabilities	2.19	0	0	24.89	0

Place: Ahmedabad
Date: May 09, 2025

FOR ADLINE CHEM LAB LIMITED



SHRI RAM PATHAK
MANAGING DIRECTOR
DIN NO: 02663344



**STANDALONE AUDITED STATEMENT OF ASSETS & LIABILITIES AS AT
MARCH 31, 2025**

(Rs in Lakhs)

Particulars	As at 31st March 2025	As at 31st March 2024
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	-	-
(b) Capital work-in-progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible assets	-	-
(f) Intangible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade receivables	-	-
(iii) Loans	-	-
(iv) Others (to be specified)	-	-
(i) Deferred Tax Assets	-	-
(j) Other non current assets	-	-
Current assets		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade Receivable	-	-
(iii) Cash and cash equivalents	6.32	4.22
(iv) Bank balances other than (iii) above	-	-
(v) Loans	-	-
(vi) Others (to be specified)	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	1.23	-
TOTAL ASSETS	7.55	4.22
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	585.00	585.00
(b) Other Equity	(733.95)	(722.20)
Non-current liabilities		
(a) Financial Liabilities	-	-
(i) Borrowings	148.78	-
(ia) Lease Liabilities	-	-
(ii) Trade payables	-	-
(iii) Other financial liabilities	-	-
(b) Provisions	0.08	0.33
(c) Deferred tax liabilities (Net)	6.08	2.77
(d) Other non-current liabilities	-	-
Current liabilities		
(a) Financial Liabilities	-	-
(i) Borrowings	-	135.84
(ia) Lease Liability	-	-
(ii) Trade payables	-	-
(iii) Other financial liabilities [other than those specified in item (c)]	-	-
(b) Other current liabilities	1.55	1.36
(c) Provisions	0.00	1.12
(d) Current Tax Liabilities (Net)	-	-
TOTAL EQUITY AND LIABILITIES	7.55	4.22




ADLINE CHEMLAB LIMITED

Standalone statement of Cash flow for the year ended March 31,2025

(Rs.in Lacs)

Particulars	01-04-2024 to 31-03-2025	01-04-2023 to 31- 03-2024
A Cash flow from Operating Activities		
Net Profit Before Tax	(20.57)	(30.28)
Adjustments for:		
Add Interest Expense	13.12	12.44
Add Interest Income		0.01
Add Provision for Gratuity	1.46	
Add Changes due to Modification in Financial Liabilities	(24.89)	
Operating Profit / (Loss) before Working Capital Changes	(30.87)	(17.82)
Adjustments for:		
Increase/(Decrease) in Other Current Liabilities	0.19	0.89
Increase/(Decrease) in Provisions	(0.83)	0.02
(Increase)/Decrease in Inventories		
(Increase)/Decrease in other current assets	(1.23)	
Cashflow generated from Operating Activities	(32.74)	(16.91)
Income Tax Paid / Income Tax Refund (Net)	(10.13)	
Net Cashflow generated from Operating Activities A	(22.61)	(16.91)
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment		
Sale of Property , Plant and Equipment		
Sale of Investments		
Purchase of Investments		
Share Application Money Received Back		
Dividend Income		
Interest Income		(0.01)
(Increase)/Decrease in short term loans & advances		
Net Cashflow generated from Investments Activities B		(0.01)
C Cash flow from Financing Activities	(22.61)	(16.92)
Share Listing & Processing Fees		
Interest Expenses	(13.12)	(12.44)
Proceedings from long term borrowing		
Repayment of long term borrowing		
Proceedings from Short term borrowing		
Repayment of Short term borrowing		
(Increase)/Decrease in other non-current assets		
(Increase) /Decrease in Short term Loans & Advances (Assets)		
Increase /(Decrease) in Borrowings (Liabilities)	37.83	
Increase/(Decrease) in Borrowing		27.42
Increase/(Decrease) in other financial liabilities		
Net Cashflow generated from Financing Activities C	24.71	14.97
Net Change in Cash & Cash Equivalents (A+B+C)	2.10	(1.95)
Opening Cash & Cash Equivalents	4.22	6.17
Closing Cash & Cash Equivalents	6.32	4.22



ADLINE CHEMLAB LIMITED

Extract of financial results for the quarter / year ended on March 31, 2025
[in terms of Regulation 47(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Particulars	(Rs in Lakhs)			
	31st March 2025		31st March 2024	
	Audited	Unaudited	Restated	Restated
Total income from operations	24.89	0.00	0.00	0.01
Net profit for the period - before tax	16.17	-13.14	-9.62	-30.28
Net profit for the period - after tax	20.94	-12.26	-8.77	-27.18
Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	20.66	-11.81	-8.73	-27.13
Equity share capital	585.00	585.00	585.00	585.00
Other equity	0.00	0.00	0.00	0.00
Earnings per equity share of 10 each (not annualised, excluding year end)				
1. Basic	0.04	-0.02	-0.01	-0.05
2. Diluted	0.04	-0.02	-0.01	-0.05

Note

The above is an extract of the detailed format of results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015



Annexure- B

The Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Applicable Circulars are given below:

Sr. No.	Particulars	Description
1.	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Appointment.
2.	Date of Appointment/re-appointment/cessation & terms of appointment/ re-appointment	9 th May, 2025
4.	Brief Profile (in case of appointment)	Mr. Rahul Doshi is Qualified Chartered Accountant holding certificate of Practice since 2004. He also holds Bachelor of Commerce. He is also DISA Qualified.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

CIN : L24231GJ1988PLC010956

ADLINE CHEM LAB LIMITED (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.
Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com

Annexure- C

The Details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Applicable Circulars are given below:

Sr. No.	Particulars	Details
1.	Reason for Change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Appointment
2.	Date of Appointment/re-appointment/cessation& terms of appointment/ re-appointment	May 9, 2025
3.	Brief Profile (in case of appointment)	Mr. Jitendra Parmar is the proprietor of Jitendra Parmar & Associates, Company Secretaries. He holds a postgraduate degree in Commerce with a specialization in Accounting and Finance and is a Fellow Member of the Institute of Company Secretaries of India (ICSI). As a Practicing Company Secretary with over 9 years of experience, he has extensive expertise in Corporate Laws, Financial Management, Income Tax Planning, GST Laws and other allied legal areas.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.

CIN : L24231GJ1988PLC010956

ADLINE CHEM LAB LIMITED (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.
Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com